Tagrisso
My Prescription
Payment
Select pharmacy
$19,311.04
Print or send this coupon to your phone
AlbertsonsPowered byAbout Tagrisso
Drug Details
Osimertinib, known by the brand name Tagrisso, is an oral medication used to treat non-small cell lung cancer (NSCLC), particularly when the cancer has specific mutations in the epidermal growth factor receptor (EGFR) gene. It is designed for patients whose cancer is either metastatic or has returned following surgery or other EGFR inhibitor treatments. Osimertinib functions by targeting and inhibiting the protein EGFR, which is critical for cell growth. In some lung cancers, mutations in the EGFR gene cause cells to grow and spread rapidly. By blocking this protein's activity, osimertinib helps to slow down or stop the growth and spread of cancer cells. While taking this medication, some patients may experience side effects such as an acne-like rash, diarrhea, and changes in heart rhythm. Always consult healthcare professionals for personalized medical advice and before starting any new treatment.
Price history for Tagrisso
30 Tablets, 80MG
Average retail price for Tagrisso
Average SaveHealth price for Tagrisso
Our price history data is based on aggregated prescription data collected from participating pharmacies in America. Our prescription data updates daily to reflect the latest price changes. If you notice a missing data point, it means there wasn't sufficient data available to generate a monetary value for that date.
*Retail prices are based on pharmacy claims data, and may not be accurate when we don't have enough claims.
Tagrisso dosage forms
| Dosage | Quantity | Price from | Per unit |
|---|---|---|---|
| 40MG | 30 Tablets | $19,311.04 | $643.70 |
| 80MG | 30 Tablets | $19,311.04 | $643.70 |
Tagrisso FAQs
The life expectancy of a person taking Tagrisso (osimertinib) can vary significantly based on individual factors such as the stage of lung cancer, overall health, and response to treatment. Clinical trials have shown that Tagrisso can improve progression-free survival and overall survival in patients with certain types of non-small cell lung cancer (NSCLC) with specific genetic mutations. However, it is important for patients to discuss their specific prognosis with their healthcare provider, as they can provide information tailored to the individual's condition and treatment response.
Tagrisso is not considered traditional chemotherapy. It is a targeted therapy, specifically a tyrosine kinase inhibitor, used to treat certain types of non-small cell lung cancer with specific genetic mutations.
Tagrisso (osimertinib) is a medication that is used to treat certain types of non-small cell lung cancer (NSCLC) that have specific mutations in the epidermal growth factor receptor (EGFR) gene. It is often prescribed for patients with stage 4 NSCLC who have these EGFR mutations. Tagrisso has been shown to be effective in targeting and inhibiting the growth of cancer cells in these cases. However, its effectiveness can vary depending on individual patient factors, and it is important for patients to discuss treatment options with their oncologist.
The average cost of Tagrisso can vary depending on factors such as location, insurance coverage, and pharmacy pricing. Without insurance, the cost can be quite high, often exceeding several thousand dollars for a 30-day supply. It is advisable for individuals to check with their specific pharmacy and insurance provider for the most accurate and personalized cost information. Additionally, there may be patient assistance programs available to help offset the cost.
When taking Tagrisso (osimertinib), it is generally advised to avoid grapefruit and grapefruit juice. Grapefruit can interfere with the metabolism of the medication, potentially leading to increased levels in the bloodstream and a higher risk of side effects. It is always best to consult with a healthcare provider for personalized dietary recommendations while on this medication.